Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe-Reference-Cited by-同舟云学术

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe

Published:2016-10-15 Issue:8 Volume:194 Page:1029-1031
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Lange Christoph^ORCID,Duarte Raquel,Fréchet-Jachym Mathilde^ORCID,Guenther Gunar,Guglielmetti Lorenzo^ORCID,Olaru Ioana D.^ORCID,Oliveira Olena^ORCID,Rumetshofer Rudolf,Veziris Nicolas^ORCID,van Leth Frank^ORCID

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference7 articles.

1. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

2. Getting Personal Perspectives on Individualized Treatment Duration in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

3. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

4. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon

5. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe;Clinical Microbiology and Infection;2024-09

2. Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings;Journal of King Saud University - Science;2024-04

3. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine;Therapeutic Advances in Respiratory Disease;2024-01

4. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland;Respiration;2024

5. Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin;Pneumologie;2023-11-06